<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117438</article-id><article-id pub-id-type="publisher-id">ACM-43788</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_13767535.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  膜联蛋白A5在围生期疾病中的研究进展
  The Research Progress of Annexin A5 in Perinatal Diseases
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>滕</surname><given-names>萌</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>静</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>一丹</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>瓮</surname><given-names>占平</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛市市立医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>大连医科大学，辽宁 大连</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3012</fpage><lpage>3017</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  膜联蛋白A5 (Anx A5)是钙依赖的磷脂结合蛋白家族的一员，其广泛存在于组织细胞中，因为其具有的独特结构而参加多种细胞内、外的抗凝、促凋亡等重要功能。近年来研究发现，膜联蛋白A5在妊娠特发疾病如子痫前期、胎儿生长受限等孕妇的血清及胎盘组织中的表达下降，与多种疾病的发生发展密切相关。现就膜联蛋白A5的生物学功能及与各种妊娠相关疾病的关系进行分析与总结，为围生期相关疾病的预防及治疗提供新思路。
   Annexin A5 (Anx A5) is a member of the calcium-dependent phospholipid binding protein family, which is widely present in tissues and cells. Because of its unique structure, it participates in a variety of important functions inside and outside the cell, such as anticoagulant and pro-apoptosis. In recent years, a large of number studies have showed that the expression of Annexin A5 in the serum and placental tissues of pregnant women with idiopathic pregnancy-related diseases such as preeclampsia, fetal growth restriction has decreased, which is closely related to the occurrence and development of many diseases. The biological function of Annexin A5 and the relationship with various pregnancy-related diseases are analyzed and summarized, which provides new ideas for the prevention and treatment of perinatal-related diseases.
 
</p></abstract><kwd-group><kwd>膜联蛋白A5，围生期疾病，抗凝，细胞融合, Annexin A5</kwd><kwd> Perinatal Disease</kwd><kwd> Anticoagulation</kwd><kwd> Cell Fusion</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>膜联蛋白A5 (Anx A5)是钙依赖的磷脂结合蛋白家族的一员，其广泛存在于组织细胞中，因为其具有的独特结构而参加多种细胞内、外的抗凝、促凋亡等重要功能。近年来研究发现，膜联蛋白A5在妊娠特发疾病如子痫前期、胎儿生长受限等孕妇的血清及胎盘组织中的表达下降，与多种疾病的发生发展密切相关。现就膜联蛋白A5的生物学功能及与各种妊娠相关疾病的关系进行分析与总结，为围生期相关疾病的预防及治疗提供新思路。</p></sec><sec id="s2"><title>关键词</title><p>膜联蛋白A5，围生期疾病，抗凝，细胞融合</p></sec><sec id="s3"><title>The Research Progress of Annexin A5 in Perinatal Diseases<sup> </sup></title><p>Meng Teng<sup>1</sup>, Jing Yu<sup>2</sup>, Yidan Pan<sup>1</sup>, Zhanping Weng<sup>2*</sup></p><p><sup>1</sup>Dalian Medical University, Dalian Liaoning</p><p><sup>2</sup>Qingdao Municipal Hospital, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/19-1572385x4_hanspub.png" /></p><p>Received: Jun. 7<sup>th</sup>, 2021; accepted: Jun. 28<sup>th</sup>, 2021; published: Jul. 9<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/19-1572385x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Annexin A5 (Anx A5) is a member of the calcium-dependent phospholipid binding protein family, which is widely present in tissues and cells. Because of its unique structure, it participates in a variety of important functions inside and outside the cell, such as anticoagulant and pro-apoptosis. In recent years, a large of number studies have showed that the expression of Annexin A5 in the serum and placental tissues of pregnant women with idiopathic pregnancy-related diseases such as preeclampsia, fetal growth restriction has decreased, which is closely related to the occurrence and development of many diseases. The biological function of Annexin A5 and the relationship with various pregnancy-related diseases are analyzed and summarized, which provides new ideas for the prevention and treatment of perinatal-related diseases.</p><p>Keywords:Annexin A5, Perinatal Disease, Anticoagulation, Cell Fusion</p><disp-formula id="hanspub.43788-formula13"><graphic xlink:href="//html.hanspub.org/file/19-1572385x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/19-1572385x8_hanspub.png" /> <img src="//html.hanspub.org/file/19-1572385x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>膜联蛋白(Annexins)是在真核细胞中发现的一类蛋白家族，在脊椎动物中ANX家族目前已发现有12个成员(ANXA1-A11, A13)，它们以Ca<sup>2+</sup>依赖的方式与负电荷磷脂膜结合 [<xref ref-type="bibr" rid="hanspub.43788-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.43788-ref2">2</xref>]。它们由70个氨基酸结构域的一个四重重复序列和一个可变的氨基酸末端(NT)结构域组成，该结构域包含各种分子伴侣的磷酸化位点和结合位点，并被认为是导致Annexins功能特异性的因素 [<xref ref-type="bibr" rid="hanspub.43788-ref2">2</xref>]。膜联蛋白A5 (Anx A5)主要由胎盘滋养细胞分泌，是一种抗凝物质，可能在围产期疾病的发生、发展中起着重要的作用。现就Anx A5的生物学特性及其在围生医学中的研究进行综述，为围产期疾病发病机制的研究及治疗提供新的思路。</p></sec><sec id="s6"><title>2. Anx A5的生物学特性</title><sec id="s6_1"><title>2.1. 结构与功能</title><p>Anx A5是Anx家族中最多、分布最广的膜联蛋白。它最初是在1970年发现于人的胎盘 [<xref ref-type="bibr" rid="hanspub.43788-ref3">3</xref>]，其基因位于染色体4q26-q28上，有13个外显子，12个内含子。其蛋白由320个氨基酸构成，分子量为35935Da。X-射线结晶学和低温电镜研究表明，Anx A5有可溶型和膜结合型两种存在方式。单体Anx A5有4个重复区域并排列成对，呈突出的圆盘形，在每个凸面上都有与磷脂和Ca<sup>2+</sup>的结合位点 [<xref ref-type="bibr" rid="hanspub.43788-ref4">4</xref>]。其立体构型非常典型，包含两种类型：II型和III型。II型即AB型，即在AB环上的Ca<sup>2+</sup>的结合位点，其结合力最高；III型即在N末端有B螺旋(B位点)和D螺旋(D位点)，其与Ca<sup>2+</sup>的结合力不高。大量研究表明，Anx A5在功能层面上，有促进细胞融合、维持细胞稳定、抗凝等功能，且与早期细胞凋亡有一定的相关性。</p></sec><sec id="s6_2"><title>2.2. Anx A5在胎盘中的表达及作用</title><p>Anx A5由血小板和胎盘滋养细胞合成，存在于胎盘绒毛表面的顶端，在母胎血液循环中起重要作用<sup> </sup> <sup>[<xref ref-type="bibr" rid="hanspub.43788-ref5">5</xref>]</sup> 。Anx A5在Ca<sup>2+</sup>存在时与带负电荷的磷脂如磷脂酰丝氨酸(PS)具有高亲和力，并在滋养层膜的外叶中表达。这样Anx A5就在滋养细胞表面的促凝阴离子磷脂周围形成了一个抗血栓的二维屏蔽层，有效地将PS这一促凝因素与其他相关促凝因子隔离开来 [<xref ref-type="bibr" rid="hanspub.43788-ref6">6</xref>]。Anx A5还可以抑制内皮细胞介导的凝血酶形成，从而起到抗凝血作用 [<xref ref-type="bibr" rid="hanspub.43788-ref7">7</xref>]。在细胞凋亡过程中，大量PS暴露在细胞表面，并能支持促凝血酶复合物的组装，从而表现出促凝和促炎活性。然而，PS与Anx A5的结合能抑制成熟胎盘细胞凋亡过程中产生的促凝血和促炎活性。</p><p>有研究 [<xref ref-type="bibr" rid="hanspub.43788-ref8">8</xref>] 证明，Anx A5参与了许多与膜相关的过程，例如囊泡转运、膜聚集、融合和细胞膜修复等。其在与生物膜结合时显示出一种自组织成二维(2D)阵列的结构特性。在聚集的滋养层细胞的质膜子集上，在E钙黏蛋白(E-cadherin)、α钙黏蛋白(α-catenin)和β钙黏蛋白(β-catenin)附近有一个Anx A5簇。钙浓度的升高触发了单体Anx A5分子与含有负电荷磷脂的膜表面的结合，这些分子随后迅速组装成三聚体，然后自组织成二维有序阵列 [<xref ref-type="bibr" rid="hanspub.43788-ref9">9</xref>]。通过二维阵列自组织参与调节滋养层融合，促进E-cadherin质膜迁移和细胞聚集，这是滋养层融合所必需的。</p><p>Severine A [<xref ref-type="bibr" rid="hanspub.43788-ref10">10</xref>] 等通过重组Anx A5细胞传递和RNA干扰来证明Anx A5在合胞体形成中的作用。通过多种免疫共沉淀、免疫定位和邻近实验，发现在一个分子复合物附近的质膜内侧叶处有一簇Anx A5池，其中包括E-cadherin、α-catenin和β-catenin，这三种蛋白质以前被证明在细胞融合过程中发挥重要作用。通过Anx A5的敲除和重组实验证明这种Anx A5 2D网络介导E-Cadherin在质膜中的迁移，从而触发了人滋养细胞的聚集，进而促进了细胞融合。</p></sec></sec><sec id="s7"><title>3. Anx A5在围产期疾病中的研究进展</title><p>在胚胎植入胎盘过程中，胎儿滋养细胞在怀孕早期侵入母体子宫内膜。细胞滋养细胞聚集并融合形成非增殖的、多核的、内分泌活性的合体滋养细胞。细胞滋养细胞在人类妊娠过程中起着至关重要的作用，它具有分化为合胞体的能力。细胞滋养细胞分化和细胞融合异常对胎儿生长发育和妊娠结局有严重影响。其特点是绒毛膜绒毛体积和表面积的减少，这在宫内生长受限和子痫前期等围产期疾病的病理特征上都有一定体现 [<xref ref-type="bibr" rid="hanspub.43788-ref11">11</xref>]。联系到Anx A5在功能层面上，有促进细胞融合、维持细胞稳定、抗凝等功能，怀疑Anx A5与围产期疾病的发生发展具有一定的相关性。</p><sec id="s7_1"><title>3.1. Anx A5与胎儿生长受限</title><p>胎儿生长受限(FGR)被定义为估计的胎儿体重和/或腹围(AC)小于第10个百分位，其在围产期疾病中的发生率较高。Sifakis S等 [<xref ref-type="bibr" rid="hanspub.43788-ref12">12</xref>] 的研究采用实时PCR和ELISA方法分别检测了18例胎儿生长受限(FGR)患者和16例正常妊娠胎盘组织中Anx A5的mRNA和蛋白水平。FGR胎盘的Anx A5 mRNA水平明显低于正常妊娠，而蛋白水平没有明显差异。对从出生体重小于第3百分位数的婴儿中获得的13例FGR影响的胎盘进行了同样的分析，结果与上述结果相似。继续对13例FGR影响的胎盘进行组织学评价。62%例胎盘中，以血栓性血管病变为主要病理表现，并伴有基底坏死、蜕膜血管血栓、大量绒毛周围纤维蛋白沉积和广泛的绒毛膜下血栓形成等胎盘血管病变。其余病例以炎症为主要特征，并伴有病因不明的血管炎、胎儿炎症反应综合征等。对这62%例组织学检查主要以血栓性血管病变为特征的病例进行统计学分析，与对照组相比，胎盘组织Anx A5mRNA水平显著降低，而蛋白质水平在两组间差异无显著性。尽管与FGR相关的胎盘和对照组的蛋白水平相似，但推测可能是血流中蛋白的募集、细胞凋亡或转录后修饰的增加影响了FGR相关胎盘中的Anx A5蛋白水平。仍需要进一步的研究揭示Anx A5在FGR病理中的作用。</p><p>Simone D等研究 [<xref ref-type="bibr" rid="hanspub.43788-ref13">13</xref>] 证明了Anx A5能与磷脂有效结合，从而抑制FGR的发展，并表示胎盘Anx A5表达的下降，对胎儿宫内发育具有一定的负面影响；Van Eerden等研究 [<xref ref-type="bibr" rid="hanspub.43788-ref14">14</xref>] 也证明携带Anx A5基因M2突变的孕妇，该蛋白表达减少会导致子宫-胎盘循环缺血缺氧，胎儿所需的营养物质均从胎盘中获取，如果胎盘氧供不足，那胎儿的生长发育将受到限制，出现体重低于正常孕周的足月胎儿的情况，因此Anx A5的变化与FGR有着一定的相关性。</p></sec><sec id="s7_2"><title>3.2. Anx A5与系统性自身免疫病</title><p>系统性自身免疫疾病(AID)是机体自身免疫功能紊乱，对自身抗原产生免疫反应，导致自身组织损伤的慢性炎性疾病，其特点是激活免疫系统，改变机体免疫状态，活化T细胞和产生自身抗体。AID多发于育龄期女性，妊娠期常见的AID包括：系统性红斑狼疮(systemic lupus erythematosus, SLE)、抗磷脂综合征(antiphospholipid syndrome, APS)等 [<xref ref-type="bibr" rid="hanspub.43788-ref15">15</xref>]。有研究表明 [<xref ref-type="bibr" rid="hanspub.43788-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.43788-ref17">17</xref>]，在系统性自身免疫性疾病，特别是系统性红斑狼疮(SLE)和抗磷脂综合征(APS)患者血液系统中Anx A5水平不稳定及其功能出现紊乱，与SLE和APS患者凝血功能的紊乱具有相关性。SLE和APS患者体内Anx A5抗体的存在干扰了其抗凝功能，抗凝活性显著降低，这一观察结果与宫内胎儿丢失、子痫前期和动脉及静脉血栓形成的高发生率相关。抗Anx A5抗体致病性的直接证据来自于输注抗Anx A5抗体导致妊娠BALB/c小鼠胎盘血栓形成和组织坏死的研究 [<xref ref-type="bibr" rid="hanspub.43788-ref18">18</xref>]。注入的抗Anx A5抗体可能与抗磷脂抗体的作用类似 [<xref ref-type="bibr" rid="hanspub.43788-ref19">19</xref>]，导致胎盘内Anx A5丢失，从而使母胎组织交界处血栓形成，影响营养交换功能，导致胎儿死亡 [<xref ref-type="bibr" rid="hanspub.43788-ref20">20</xref>]。</p><p>近年来还有研究 [<xref ref-type="bibr" rid="hanspub.43788-ref21">21</xref>] 表明，PS的暴露作为凝血过程的信号，细胞外的Anx A5识别信号并粘附在PS上形成一道抗凝屏障，防止狼疮相关血栓的形成。由于Anx A5是磷脂辅助因子，会被误认为磷脂蛋白复合物，从而成为抗磷脂抗体攻击的目标。另外 [<xref ref-type="bibr" rid="hanspub.43788-ref22">22</xref>]，抗磷脂抗体黏合β2糖蛋白I对磷脂有更高的亲和力，从而与Anx A5竞争黏合磷脂，降低了Anx A5的抗凝能力，导致血栓形成，更有甚者导致胎儿宫内死亡。</p></sec><sec id="s7_3"><title>3.3. Anx A5与子痫前期</title><p>子痫前期(preeclampsia, PE)是一种主要发生在妊娠20周以后的临床综合征，主要表现为高血压、蛋白尿等多系统器官功能紊乱。PE是导致胎儿畸形、胎儿宫内生长受限和孕产妇死亡的常见原因。PE的发病起源于胎盘的病理生理变化，由于免疫、遗传、内皮细胞功能紊乱等因素，滋养细胞分化异常导致螺旋动脉重铸失败和胎盘浅着床 [<xref ref-type="bibr" rid="hanspub.43788-ref23">23</xref>]，其主要表现为胎盘局部缺血或缺氧，与体内凝血系统和抗凝血系统的失衡密切相关。有研究 [<xref ref-type="bibr" rid="hanspub.43788-ref24">24</xref>] 发现在子痫前期的胎盘滋养细胞中的Anx A5的表达与正常胎盘相比染色强度降低，随着Anx A5表达的降低，患者血浆纤维蛋白降解产物和凝血酶–抗凝血酶III复合物水平升高。这些结果提示子痫前期胎盘中Anx A5表达降低可能导致绒毛间隙高凝状态，并可能与宫内生长受限的发生有关。</p><p>Hong Xin等的研究 [<xref ref-type="bibr" rid="hanspub.43788-ref25">25</xref>] 采用蛋白印迹法和免疫组化方法检测孕妇胎盘组织及外周血中的Anx A5蛋白表达水平，结果显示子痫前期无论早发型还是晚发型的胎盘组织及外周血中Anx A5蛋白水平均低于健康孕妇组，而子痫前期各组之间没有明显统计学差异。然而子痫前期患者外周血的凝血功能未见明显变化，认为这可能与外周血中Anx A5下降不明显有关。有研究 [<xref ref-type="bibr" rid="hanspub.43788-ref26">26</xref>] 表明，Anx A5的抗凝活性同其水平密切相关。活化部分凝血酶时间(APTT)与Anx A5水平呈依赖性相关。当Anx A5水平 ≥ 30 mg/L时，才能完全阻止凝血酶复合物的形成。该研究认为子痫前期Anx A5的表达下调与血管重铸障碍存在着相关性。特别是Anx A5抗凝作用的下降可导致胎盘微循环的凝血功能障碍，与子痫前期的发病、进展有关。</p></sec></sec><sec id="s8"><title>4. 结语</title><p>综上所述，虽然各种疾病的发病机制不同，但在多种妊娠相关疾病中Anx A5均呈现低表达状态，即使具体的发病机制暂未明确，但可以肯定，低表达的Anx A5影响疾病的发生发展过程。因此，深入研究Anx A5在围生期疾病中的作用，将为围生期疾病的治疗提供新的思路。或许将来可以通过大样本数据的研究，制定Anx A5在不同类型疾病中的范围，通过检测Anx A5的含量，在临床症状出现之前早期预测疾病的发生，通过早发现、早诊断、早治疗来改善围生期母儿的预后。</p></sec><sec id="s9"><title>文章引用</title><p>滕 萌,于 静,潘一丹,瓮占平. 膜联蛋白A5在围生期疾病中的研究进展The Research Progress of Annexin A5 in Perinatal Diseases[J]. 临床医学进展, 2021, 11(07): 3012-3017. https://doi.org/10.12677/ACM.2021.117438</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43788-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Moss, S.E. and Morgan, R.O. (2004) The Annexins. Genome Biology, 5, 1-8. &lt;br&gt;https://doi.org/10.1186/gb-2004-5-4-219</mixed-citation></ref><ref id="hanspub.43788-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Gerke, V., Creutz, C.E. and Moss, S.E. (2005) Annexins: Linking Ca2+ Signalling to Membrane Dynamics. Nature Reviews Molecular Cell Biology, 6, 449-461. &lt;br&gt;https://doi.org/10.1038/nrm1661</mixed-citation></ref><ref id="hanspub.43788-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bohn, H. and Kraus, W. (1979) Isolation and Characterization of a New Placenta Specific Protein (PP10) (Author’s Transl). Archives of Gynecology, 227, 125-134. &lt;br&gt;https://doi.org/10.1007/BF02103286</mixed-citation></ref><ref id="hanspub.43788-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Cookson, B.T., Engelhardt, S., Smith, C., et al. (1994) Organization of the Human Annexin V (ANX5) Gene. Genomics, 20, 463-467. &lt;br&gt;https://doi.org/10.1006/geno.1994.1201</mixed-citation></ref><ref id="hanspub.43788-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wu, X.-X., Arslan, A.A., Wein, R., et al. (2006) Analysis of Circulating Annexin A5 Parameters during Pregnancy: Absence of Differences between Women with Recurrent Spontaneous Pregnancy Losses and Controls. American Journal of Obstetrics and Gynecology, 195, 971. &lt;br&gt;https://doi.org/10.1016/j.ajog.2006.02.034</mixed-citation></ref><ref id="hanspub.43788-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rand, J.H., Wu, X.X., Quinn, A.S., Chen, P.P., McCrae, K.R., Bovill, E.G., et al. (2003) Human Monoclonal Antiphospholipid Antibodies Disrupt the Annexin A5 Anticoagulant Crystal Shield on Phospholipid Bilayers: Evidence from Atomic Force Microscopy and Functional Assay. The American Journal of Pathology, 163, 1193-1200.  
&lt;br&gt;https://doi.org/10.1016/S0002-9440(10)63479-7</mixed-citation></ref><ref id="hanspub.43788-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Shyu, V.B.H., Hsu, C.E., Wen, C.J., et al. (2017) Novel Injury Site Targeted Fusion Protein Comprising Annexin V and Kunitz Inhibitor Domains Ameliorates Ischemia-Reperfusion Injury and Promotes Survival of Ischemic Rat Abdominal Skin Flaps. Annals of Plastic Surgery, 78, S129-S134. &lt;br&gt;https://doi.org/10.1097/SAP.0000000000001018</mixed-citation></ref><ref id="hanspub.43788-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Bouter, A., Carmeille, R., Gounou, C., Bouvet, F., Degrelle, S.A., Evain-Brion, D. and Brisson, A.R. (2015) Review: Annexin-A5 and Cell Membrane Repair. Placenta, 36, S43-S49. &lt;br&gt;https://doi.org/10.1016/j.placenta.2015.01.193</mixed-citation></ref><ref id="hanspub.43788-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Carmeille, R., Degrelle, S.A., Plawinski, L., et al. (2015) Annexin-A5 Promotes Membrane Resettling in Human Trophoblasts. Biochimica et Biophysica Acta, 1853, 2033-2044. &lt;br&gt;https://doi.org/10.1016/j.bbamcr.2014.12.038</mixed-citation></ref><ref id="hanspub.43788-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Degrelle, S.A., Gerbaud, P., Leconte, L., et al. (2017) Annexin-A5 Organized in 2D-Network at the Plasmalemma Eases Human Trophoblast Fusion. Scientific Reports, 7, Article No. 42173. &lt;br&gt;https://doi.org/10.1038/srep42173</mixed-citation></ref><ref id="hanspub.43788-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Gerke, V. and Moss, S.E. (2002) Annexins: From Structure to Function. Physiological Reviews, 82, 331-371.  
&lt;br&gt;https://doi.org/10.1152/physrev.00030.2001</mixed-citation></ref><ref id="hanspub.43788-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Sifakis, S., Soufla, G., Koukoura, O., et al. (2010) Decreased Annexin A5 mRNA Placental Expression in Pregnancies Complicated by Fetal Growth Restriction. Thrombosis Research, 125, 326-331.  
&lt;br&gt;https://doi.org/10.1016/j.thromres.2009.11.033</mixed-citation></ref><ref id="hanspub.43788-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ornaghi, S., Vergani, P., Urban, G., Giardini, V., Moltrasio, F. and Leone, B.E. (2011) Immunohistochemical Expression of Annexin A5 in Preeclamptic Placentas. Placenta, 32, 264-268. &lt;br&gt;https://doi.org/10.1016/j.placenta.2010.12.015</mixed-citation></ref><ref id="hanspub.43788-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Van Eerden, P., Wu, X.-X., et al. (2007) Annexin A5 Levels in Midtrimester Amniotic Fluid: Association with Intrauterine Growth Restriction. American Journal of Obstetrics and Gynecology, 194, 1371-1376.  
&lt;br&gt;https://doi.org/10.1016/j.ajog.2005.11.005</mixed-citation></ref><ref id="hanspub.43788-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">De Carolis, S., Moresi, S., Rizzo, F., Monteleone, G., Tabacco, S., Salvi, S., Garufi, C. and Lanzone, A. (2019) Autoimmunity in Obstetrics and Autoimmune Diseases in Pregnancy. Best Practice and Research: Clinical Obstetrics and Gynaecology, 60, 66-76. &lt;br&gt;https://doi.org/10.1016/j.bpobgyn.2019.03.003</mixed-citation></ref><ref id="hanspub.43788-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Chen, L., Liang, X.J., et al. (2012) Annexin A5 Protein Expression Is Associated with the Histological Differentiation of Uterine Cervical Squamous Cell Carcinoma in Patients with an Increased Serum Concentration. Molecular Medicine Reports, 6, 1249-1254. &lt;br&gt;https://doi.org/10.3892/mmr.2012.1078</mixed-citation></ref><ref id="hanspub.43788-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Avriel, A., Fleischer, S., Friger, M., et al. (2016) Prediction of Antiphospholipid Syndrome Using Annexin A5 Competition Assay in Patients with SLE. Clinical Rheumatology, 35, 2933-2938.  
&lt;br&gt;https://doi.org/10.1007/s10067-016-3428-1</mixed-citation></ref><ref id="hanspub.43788-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X., Campos, B., Kaetzel, M.A. and Dedman, J.R. (1999) Annexin V Is Critical in the Maintenance of Murine Placental Integrity. American Journal of Obstetrics &amp; Gynecology, 180, 1008-1016.  
&lt;br&gt;https://doi.org/10.1016/S0002-9378(99)70674-5</mixed-citation></ref><ref id="hanspub.43788-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Omar, G., Mohamed, F.I., Sadek, H.A. and Mamdouh, A. (2018) Diagnostic Value of Anti-Annexin A5 Antibodies in Seropositive versus Seronegative Antiphospholipid Syndrome Patients. Egyptian Rheumatologist, 40, 111-116.  
&lt;br&gt;https://doi.org/10.1016/j.ejr.2017.07.003</mixed-citation></ref><ref id="hanspub.43788-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Rand, J.H., Wu, X.X., Andree, H.A.M., Lockwood, C.J., Guller, S., Scher, J. and Harpel, P.C. (1997) Pregnancy Loss in the Antiphospholipid-Antibody Syndrome—A Possible Thrombogenic Mechanism. The New England Journal of Medicine, 337, 154-160. &lt;br&gt;https://doi.org/10.1056/NEJM199707173370303</mixed-citation></ref><ref id="hanspub.43788-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Hrycek, A. and Cielik, P. (2012) Annexin A5 and Anti-Annexin Antibodies in Patients with Systemic Lupus Erythematosus. Rheumatology International, 32, 1335-1342. &lt;br&gt;https://doi.org/10.1007/s00296-011-1793-2</mixed-citation></ref><ref id="hanspub.43788-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wahezi, D.M., Ilowite, N.T., Wu, X.X., et al. (2013) Annexin A5 Anticoagulant Activity in Children with Systemic Lupus Erythematosus and the Association with Antibodies to DOMAIN I of beta2-Glycoprotein I. Lupus, 22, 702-711.  
&lt;br&gt;https://doi.org/10.1177/0961203313490241</mixed-citation></ref><ref id="hanspub.43788-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Gathiram, P. and Moodley, J. (2016) Pre-Eclampsia: Its Pathogenesis and Pathophysiolgy. Cardiovascular Journal of Africa, 27, 71-78. &lt;br&gt;https://doi.org/10.5830/CVJA-2016-009</mixed-citation></ref><ref id="hanspub.43788-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Shu, F., Sugimura, M., Kanayama, N., et al. (2000) Immunohistochemical Study of Annexin V Expression in Placentae of Preeclampsia. Gynecologic and Obstetric Investigation, 49, 17-23. &lt;br&gt;https://doi.org/10.1159/000010206</mixed-citation></ref><ref id="hanspub.43788-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Hong, X. and Wang, H.L. (2011) Expression Changes and Clinical Significance of Annexin V in Maternal Blood and Placenta in Patients with Preeclampsia. Chinese Journal of Obstetrics and Gynecology, 46, 88-93.</mixed-citation></ref><ref id="hanspub.43788-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Rand, J.H., Wu, X.X., et al. (2004) Detection of Antibody Mediated Reduction of Annexin A5 Anticoagulant Activity in Plasnms of Patients with the Antiphospholipid Syndrome. Blood, 104, 2783-2790.  
&lt;br&gt;https://doi.org/10.1182/blood-2004-01-0203</mixed-citation></ref></ref-list></back></article>